A clinical study to evaluate and compare the effects of three drug formulations, Tazarotene microsphere cream, Differin gel and Tazorac cream when applied topically in patients with facial acne
Phase 2
Completed
- Conditions
- Health Condition 1: null- Moderate Facial Acne Vulgaris
- Registration Number
- CTRI/2009/091/000782
- Lead Sponsor
- Promius Pharma
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
1.Male and female patients aged 12 to 50 years, with a diagnosis of moderate facial acne vulgaris.
2.Facial inflammatory lesion count >20 and < 50 (both inclusive), non-inflammatory lesions count of atleast 20-100 and IGA score = 3.
Exclusion Criteria
Patients with 2 nodulocystic lesions, prior topical acne treatment or systemic anti-inflammatory agents in past 14 days, Systemic corticosteroids, antibacterials, immunosuppressant drugs or abradent facial procedures in the past 30 days, patients with other concurrent facial skin disease and patients who are photosensitive or who are likely to engage in activities that involve excessive or prolonged exposure to sunlight.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method